| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3a40324ae67232857fbb2eda604e15a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59546069b0fbe7f96c7613f82f789b80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_209305fecb6b06e73866af4986603bde |
| publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020224530-A1 |
| titleOfInvention |
LOW IMMUNOGENICITY ANTI-TNF-α HUMANIZED MONOCLONAL ANTIBODY TCX063 AND APPLICATION THEREOF |
| abstract |
Relating to the field of biotechnology, and relating in particular to a low immunogenicity anti-TNF-α humanized monoclonal antibody TCX063 and an application thereof. Provided is the anti-TNF-α humanized monoclonal antibody TCX063, which is an anti-TNF-α humanized monoclonal antibody that has reduced immunogenicity obtained by means of modifying an FR region of an Infliximab monoclonal antibody. The provided antibody has the same TNF-α antigen binding site as the Infliximab monoclonal antibody and retains the antigen affinity and specificity of the Infliximab monoclonal antibody, but the immunogenicity of the provided anitbody is significantly lower than that of the Infliximab monoclonal antibody. The low immunogenicity TNF-α antibody will: reduce the risk of drug side effects caused by the immune response induced by the antibody immunogenicity in the human body; reduce the antibody drug ADA; extend the half-life of the antibody in vivo; and at the same time, the subcutaneous administration means is rendered possible. Thus, the present antibody has great application potential and value. |
| priorityDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |